You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonists for Peripheral Pain

    SBC: HALIMED PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Treatment of peripheral pain of various origins remains a major unmet medical need, affecting tens to hundreds of millions of people nationwide at some time during their lives. Kappa-opioid agonists have been shown in peripheral pain models to be particularly efficacious but suffer from centrally mediated effects that have limited their development. Perhaps the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Engineered Neurotensin Fragments Targeting Neuropathic Pain

    SBC: JT Pharmaceuticals, Inc.            Topic: NIDCR

    DESCRIPTION (provided by applicant): Neuropathic pain management is a major unmet clinical need. Classically used medications, including opioids and non-opioids (primarily NSAIDs), have major side effects associated with their use, and many individuals donot respond to any medications. Neuropathic pain drugs with novel mechanisms of action are being sought as an alternative; however, the only succ ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a lasmiditan analogue for treatment of acute kidney injury

    SBC: Mitohealth, Inc            Topic: NIDDK

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a safe and efficacious therapeutic small molecule for treatment of acute kidney injury (AKI). AKI results from diverse insults such as sepsis, ischemia-reperfusion (I/R)or nephrotoxicant exposure and nearly half of those who develop AKI do not survive. Since treatment remains largely palliative and survival rates ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. A Wnt Modulator for Treatment of Age-related Macular Degeneration

    SBC: Charlesson, LLC            Topic: NEI

    PROJECT SUMMARY/ABSTRACT Age-related macular degeneration (AMD) is characterized by progressively decreased central vision and visual acuity and remains a leading cause of vision loss and blindness in aged Americans. Currently, the standard of care for AMD is intravitreal vascular endothelial growth factor (VEGF) inhibitors. Clinical studies have demonstrated that anti-VEGF drugs can slow or reve ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Hydrocyanine Probes for the Accurate Detection of Reactive Oxygen Species

    SBC: LI-COR BIOSCIENCES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Reactive oxygen species (ROS) are involved in numerous cell-signaling pathways. They have been implicated in over 150 diseases including cancer, arthritis, Parkinson's disease, diabetes, myocardial infarction and atherosclerosis. The need to understand the role of ROS in these processes is evidenced by the 80,000 publications in this field during the last ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Lessons from Nature: Antifreeze Glycolipids for Cryopreservation of Mammalian Cel

    SBC: Cell & Tissue Systems, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Storage of cells for many researchers simply involves addition of 10% DMSO or similar cryoprotectants to cells in suspension, putting them in cryovials and slow cooling to subzero temperaturesf and storage in a mechanical or nitrogen cooled freezer or dewar. As long as viable cells are present upon thawing, cell yield may be a secondary consideration due to the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Selectively Absorbable Surgical Mesh for Hernia Repair

    SBC: POLY-MED, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Hernia repair is one of the most frequently performed surgical operations in the United States with approximately 800,000 procedures performed annually. The vast majority of these repairs employ a tension- free repairtechnique which involves the use of synthetic surgical meshes. Existing mesh technology is designed to be of high strength to produce a perceive ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Developing the Dietary Inflammatory Index for Clinical Application

    SBC: Connecting Health Innovations, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): A large, persuasive, and ever-increasing body of evidence links chronic inflammation to virtually all of the chronic diseases that cause the majority of disability and death in the U.S., including diabetes, cardiovascular diseases (CVD), and cancer. Diet plays a central role in the regulation of chronic inflammation. However, until we developed the dietary infl ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Small blood pumps for small patients

    SBC: Vadovations, Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Heart failure and congenital heart defects threaten the lives of several thousand children each year. The only FDA-approved long term pediatric heart support device is the Berlin Heart Excor, which is based on 30+ year old technology and is fraught with complications including blood clots forming in the device requiring frequent device replacement. The recipients of this ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government